All In Biotech

NDA 050141 · King Pharms LLC

Bicillin L-A

Penicillin G Benzathine · Injection

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1952

Jun 27, 1952

Approved uses

5

Original approval plus efficacy supplements

Registered trials

802

170 Phase 3, 84 recruiting

FAERS reports

1,363

496 serious, 39 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Prior to administration of this drug, carefully read the WARNINGS , ADVERSE REACTIONS , and DOSAGE AND ADMINISTRATION sections of the labeling. WARNING NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Prior to administration of this drug, carefully read the WARNINGS , ADVERSE REACTIONS , and DOSAGE AND ADMINISTRATION sections of the labeling.

What it is approved for

From the label in effect Jul 21, 2026.

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.

Mechanism: Mechanism of Action Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 16, 1982 Supplement 210 · Efficacy
  • Jun 22, 1955 Supplement 34 · Efficacy
  • Feb 2, 1955 Supplement 29 · Efficacy
  • Oct 21, 1954 Supplement 24 · Efficacy
  • Jun 27, 1952 Original approval
2 products under this application
  • BICILLIN L-A · PENICILLIN G BENZATHINE 300,000 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • BICILLIN L-A · PENICILLIN G BENZATHINE 600,000 UNITS/ML · INJECTABLE, INJECTION · Prescription · TE BC

Clinical trials

Interventional ClinicalTrials.gov studies with "Penicillin G Benzathine" as an intervention, any sponsor and status, largest first.

All 802 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • recalled product administered573
  • drug hypersensitivity67
  • injection site pain63
  • off label use45
  • embolia cutis medicamentosa44
  • pain43
  • drug ineffective33
  • acute kidney injury31
  • rash28
  • diarrhoea26
  • no adverse event25
  • headache24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
20056
20066
20074
200817
20098
201051
201124
201224
201313
201410
201520
201630
201736
201834
201986
202068
202139
202288
202362
202462
2025622
202643

Recalls

2 FDA enforcement reports for this application.

  • Jul 10, 2025 · Class II · Ongoing

    CGMP Deviations; particulates identified during visual inspection

  • Jul 10, 2025 · Class II · Ongoing

    CGMP Deviations; particulates identified during visual inspection

Shortages

FDA's drug shortage list.

  • Current · updated Nov 6, 2026

    Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10). Other

  • Current · updated Nov 6, 2026

    Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10). Other

  • Current · updated Nov 6, 2026

    Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bicillin L-A (Penicillin G Benzathine)

2024 spending

$4.5M

Beneficiaries

2,649

4,605 claims

Per beneficiary

$1,682

$145.83 per unit

View as table
YearSpending
2020$3,130,430
2021$3,346,269
2022$3,738,217
2023$3,968,413
2024$4,456,479

Part B: Bicillin L-A (Penicillin G Benzathine) · HCPCS J0561

2024 spending

$2.3M

Beneficiaries

3,543

5,658 claims

Per beneficiary

$647

2024 ASP limit $23.02 per unit

View as table
YearSpending
2020$2,007,911
2021$2,105,223
2022$2,434,151
2023$2,498,017
2024$2,292,754

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: King Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.